• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CDX
Click for more information
6.67% 14.0¢

CARDIEX LIMITED - Announcements

Market Cap $17.65M  ! watchlist Created with Sketch. Add to my watchlist

CardieX Limited is an Australia-based digital health technology company. The Company... CardieX Limited is an Australia-based digital health technology company. The Company develops and markets noninvasive patient monitoring technologies for assessing cardiovascular health. It specializes in the development of biomarkers and digital solutions for large-scale cardiovascular health disorders. Its solutions are designed to be deployed at point-of-care for arterial health screening, and as part of a remote patient monitoring regimen to extend care and enhance cardiovascular health outcomes. Its suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders all based on the Company’s SphygmoCor vascular biomarker technology. Its products include CONNEQT Pulse, SphygmoCor XCEL, and Oscar 2 Ambulatory Blood Pressure Monitor. CONNEQT Pulse measures both brachial and central blood pressures alongside a suite of vascular biomarkers to provide unparalleled insights into vascular health.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CDX Completion of Share Purchase Plan22/09/17
CDX Viking Yacht Company adds SphygmoCor for Employee Wellness14/09/17
CDX Security Purchase PlanPRICE SENSITIVE08/09/17
CDX Full Year Statutory AccountsPRICE SENSITIVE31/08/17
CDX Share Purchase PlanPRICE SENSITIVE29/08/17
CDX Cleansing Notice16/08/17
CDX Appendix 3B15/08/17
CDX Share PlacementPRICE SENSITIVE08/08/17
CDX Trading HaltPRICE SENSITIVE04/08/17
CDX AtCor restructures operationsPRICE SENSITIVE02/08/17
CDX AtCor Signs New AgreementPRICE SENSITIVE31/07/17
CDX Secures $0.8 million new pharmaceutical trials contractsPRICE SENSITIVE12/07/17
CDX AtCor Signs New Network Health Systems AgreementPRICE SENSITIVE07/06/17
CDX Business update and Strategic ReviewPRICE SENSITIVE18/05/17
CDX Half Yearly Report and AccountsPRICE SENSITIVE24/02/17
CDX AtCor Signs Local Health System AgreementPRICE SENSITIVE23/02/17
CDX Study Finds Central Aortic Waveform Improves HF TreatmentPRICE SENSITIVE16/02/17
CDX Tax refundPRICE SENSITIVE14/02/17
CDX Central Blood Pressure Associated with Cognitive Decline25/01/17
CDX Positive Novartis drug trial using SphygmoCor XCELPRICE SENSITIVE23/01/17
CDX Change of Director's Interest Notice x 323/12/16
CDX Appendix 3B23/12/16
CDX Results of Meeting21/12/16
CDX Cleansing Notice22/11/16
CDX Appendix 3B22/11/16
CDX Notice of General Meeting/Proxy Form18/11/16
CDX AtCor completes share placementPRICE SENSITIVE16/11/16
CDX Trading HaltPRICE SENSITIVE14/11/16
CDX Leading research team highlights role of SphygmoCorPRICE SENSITIVE04/11/16
CDX Results of Meeting-ACG.AX 28/10/16
CDX Chairmans address to AGM-ACG.AX 28/10/16
CDX Investor presentation-ACG.AX 25/10/16
CDX Change of Director's Interest Notice-ACG.AX 24/10/16
CDX Appendix 3B - option exercise-ACG.AX 24/10/16
CDX AtCor wins Frost & Sullivan's 2016 Diagnostic Devices award-ACG.AX 18/10/16
CDX Ceasing to be a substantial holder from AEF,AEF-ACG.AX 30/09/16
CDX Change in substantial holder from AEF,AEF-ACG.AX 28/09/16
CDX Appendix 4G/Corporate Governance statement-ACG.AX 26/09/16
CDX Annual Report to shareholders-ACG.AX 26/09/16
CDX Notice of Annual General Meeting/Proxy Form-ACG.AX 26/09/16
CDX AtCor launches key opinion leader webinar series-ACG.AX 26/09/16
CDX FY2016 results-ACG.AX PRICE SENSITIVE30/08/16
CDX Full Year Statutory Accounts-ACG.AX PRICE SENSITIVE30/08/16
CDX CEO presentation to BioShares Conference-ACG.AX 29/07/16
CDX Appendix 3B-ACG.AX 21/07/16
CDX Large national plan to reimburse SphygmoCor test-ACG.AX PRICE SENSITIVE07/07/16
CDX $0.6 million pharmaceutical trial extension-ACG.AX PRICE SENSITIVE29/06/16
CDX Change of Director's Interest Notice-ACG.AX 21/06/16
CDX Appendix 3B-ACG.AX 21/06/16
CDX Investor Presentation-ACG.AX 02/05/16
CDX Tax refundPRICE SENSITIVE14/03/16
CDX Patent granted in USAPRICE SENSITIVE09/03/16
CDX FDA clearance for Oscar 2 with SphygmoCor insidePRICE SENSITIVE03/03/16
CDX CPT-1 Reimbursement UpdatePRICE SENSITIVE29/02/16
CDX Appendix 3B17/02/16
CDX Patent granted in JapanPRICE SENSITIVE17/02/16
CDX Half Yearly Report and AccountsPRICE SENSITIVE12/02/16
CDX Appendix 3B11/02/16
CDX US$0.6m new pharmaceutical trial contractPRICE SENSITIVE05/02/16
CDX Appendix 3B02/02/16
CDX Appendix 3B22/01/16
CDX Market updatePRICE SENSITIVE08/01/16
CDX AtCor and A&D sign multiyear distribution contract for JapanPRICE SENSITIVE16/12/15
CDX Renal Physicians Association and CPT code communication24/11/15
CDX Change of Director's Interest Notice x 418/11/15
CDX Final Director's Interest Notice18/11/15
CDX Initial Director's Interest Notice18/11/15
CDX Results of Meeting13/11/15
CDX Chairman's Address to Shareholders13/11/15
CDX Investor presentation06/11/15
CDX Change in substantial holding from AEF05/11/15
CDX US Medicare payment for new category 1 code announcedPRICE SENSITIVE02/11/15
CDX Appointment of new Director14/10/15
CDX Annual Report to shareholders13/10/15
CDX Appendix 4G/Corporate Governance Statement13/10/15
CDX Notice of Annual General Meeting/Proxy Form13/10/15
CDX Appendix 3B16/09/15
CDX Ceasing to be a substantial holder from OCP21/08/15
CDX App 4E / Full Year Statutory AccountsPRICE SENSITIVE20/08/15
CDX Change in substantial holding11/08/15
CDX Change of Director's Interest Notice x 429/07/15
CDX American Heart Assoc new statement on arterial stiffness28/07/15
CDX Top 20 securityholders23/07/15
CDX Appendix 3B23/07/15
CDX Rights issue update21/07/15
CDX Notice of despatch of rights issue documents02/07/15
CDX Rights offer bookletPRICE SENSITIVE01/07/15
CDX Becoming a substantial holder from AEF25/06/15
CDX Letter to shareholders - rights issue24/06/15
CDX Appendix 3B23/06/15
CDX Cleansing notice23/06/15
CDX Letter to optionholders - rights issue23/06/15
CDX Appendix 3B - rights18/06/15
CDX Successful share placement and rights issuePRICE SENSITIVE17/06/15
CDX Trading HaltPRICE SENSITIVE15/06/15
CDX Expert panel guidelines for central waveform analysisPRICE SENSITIVE28/05/15
CDX Investor presentation04/05/15
CDX CE Mark for Oscar 2 with SphygmoCor InsidePRICE SENSITIVE04/05/15
CDX Appendix 3B31/03/15
CDX Appendix 3B24/03/15
CDX Completion of Share Purchase Plan
22/09/17
CDX Viking Yacht Company adds SphygmoCor for Employee Wellness
14/09/17
CDX Security Purchase Plan
08/09/17PRICE SENSITIVE
CDX Full Year Statutory Accounts
31/08/17PRICE SENSITIVE
CDX Share Purchase Plan
29/08/17PRICE SENSITIVE
CDX Cleansing Notice
16/08/17
CDX Appendix 3B
15/08/17
CDX Share Placement
08/08/17PRICE SENSITIVE
CDX Trading Halt
04/08/17PRICE SENSITIVE
CDX AtCor restructures operations
02/08/17PRICE SENSITIVE
CDX AtCor Signs New Agreement
31/07/17PRICE SENSITIVE
CDX Secures $0.8 million new pharmaceutical trials contracts
12/07/17PRICE SENSITIVE
CDX AtCor Signs New Network Health Systems Agreement
07/06/17PRICE SENSITIVE
CDX Business update and Strategic Review
18/05/17PRICE SENSITIVE
CDX Half Yearly Report and Accounts
24/02/17PRICE SENSITIVE
CDX AtCor Signs Local Health System Agreement
23/02/17PRICE SENSITIVE
CDX Study Finds Central Aortic Waveform Improves HF Treatment
16/02/17PRICE SENSITIVE
CDX Tax refund
14/02/17PRICE SENSITIVE
CDX Central Blood Pressure Associated with Cognitive Decline
25/01/17
CDX Positive Novartis drug trial using SphygmoCor XCEL
23/01/17PRICE SENSITIVE
CDX Change of Director's Interest Notice x 3
23/12/16
CDX Appendix 3B
23/12/16
CDX Results of Meeting
21/12/16
CDX Cleansing Notice
22/11/16
CDX Appendix 3B
22/11/16
CDX Notice of General Meeting/Proxy Form
18/11/16
CDX AtCor completes share placement
16/11/16PRICE SENSITIVE
CDX Trading Halt
14/11/16PRICE SENSITIVE
CDX Leading research team highlights role of SphygmoCor
04/11/16PRICE SENSITIVE
CDX Results of Meeting-ACG.AX
28/10/16
CDX Chairmans address to AGM-ACG.AX
28/10/16
CDX Investor presentation-ACG.AX
25/10/16
CDX Change of Director's Interest Notice-ACG.AX
24/10/16
CDX Appendix 3B - option exercise-ACG.AX
24/10/16
CDX AtCor wins Frost & Sullivan's 2016 Diagnostic Devices award-ACG.AX
18/10/16
CDX Ceasing to be a substantial holder from AEF,AEF-ACG.AX
30/09/16
CDX Change in substantial holder from AEF,AEF-ACG.AX
28/09/16
CDX Appendix 4G/Corporate Governance statement-ACG.AX
26/09/16
CDX Annual Report to shareholders-ACG.AX
26/09/16
CDX Notice of Annual General Meeting/Proxy Form-ACG.AX
26/09/16
CDX AtCor launches key opinion leader webinar series-ACG.AX
26/09/16
CDX FY2016 results-ACG.AX
30/08/16PRICE SENSITIVE
CDX Full Year Statutory Accounts-ACG.AX
30/08/16PRICE SENSITIVE
CDX CEO presentation to BioShares Conference-ACG.AX
29/07/16
CDX Appendix 3B-ACG.AX
21/07/16
CDX Large national plan to reimburse SphygmoCor test-ACG.AX
07/07/16PRICE SENSITIVE
CDX $0.6 million pharmaceutical trial extension-ACG.AX
29/06/16PRICE SENSITIVE
CDX Change of Director's Interest Notice-ACG.AX
21/06/16
CDX Appendix 3B-ACG.AX
21/06/16
CDX Investor Presentation-ACG.AX
02/05/16
CDX Tax refund
14/03/16PRICE SENSITIVE
CDX Patent granted in USA
09/03/16PRICE SENSITIVE
CDX FDA clearance for Oscar 2 with SphygmoCor inside
03/03/16PRICE SENSITIVE
CDX CPT-1 Reimbursement Update
29/02/16PRICE SENSITIVE
CDX Appendix 3B
17/02/16
CDX Patent granted in Japan
17/02/16PRICE SENSITIVE
CDX Half Yearly Report and Accounts
12/02/16PRICE SENSITIVE
CDX Appendix 3B
11/02/16
CDX US$0.6m new pharmaceutical trial contract
05/02/16PRICE SENSITIVE
CDX Appendix 3B
02/02/16
CDX Appendix 3B
22/01/16
CDX Market update
08/01/16PRICE SENSITIVE
CDX AtCor and A&D sign multiyear distribution contract for Japan
16/12/15PRICE SENSITIVE
CDX Renal Physicians Association and CPT code communication
24/11/15
CDX Change of Director's Interest Notice x 4
18/11/15
CDX Final Director's Interest Notice
18/11/15
CDX Initial Director's Interest Notice
18/11/15
CDX Results of Meeting
13/11/15
CDX Chairman's Address to Shareholders
13/11/15
CDX Investor presentation
06/11/15
CDX Change in substantial holding from AEF
05/11/15
CDX US Medicare payment for new category 1 code announced
02/11/15PRICE SENSITIVE
CDX Appointment of new Director
14/10/15
CDX Annual Report to shareholders
13/10/15
CDX Appendix 4G/Corporate Governance Statement
13/10/15
CDX Notice of Annual General Meeting/Proxy Form
13/10/15
CDX Appendix 3B
16/09/15
CDX Ceasing to be a substantial holder from OCP
21/08/15
CDX App 4E / Full Year Statutory Accounts
20/08/15PRICE SENSITIVE
CDX Change in substantial holding
11/08/15
CDX Change of Director's Interest Notice x 4
29/07/15
CDX American Heart Assoc new statement on arterial stiffness
28/07/15
CDX Top 20 securityholders
23/07/15
CDX Appendix 3B
23/07/15
CDX Rights issue update
21/07/15
CDX Notice of despatch of rights issue documents
02/07/15
CDX Rights offer booklet
01/07/15PRICE SENSITIVE
CDX Becoming a substantial holder from AEF
25/06/15
CDX Letter to shareholders - rights issue
24/06/15
CDX Appendix 3B
23/06/15
CDX Cleansing notice
23/06/15
CDX Letter to optionholders - rights issue
23/06/15
CDX Appendix 3B - rights
18/06/15
CDX Successful share placement and rights issue
17/06/15PRICE SENSITIVE
CDX Trading Halt
15/06/15PRICE SENSITIVE
CDX Expert panel guidelines for central waveform analysis
28/05/15PRICE SENSITIVE
CDX Investor presentation
04/05/15
CDX CE Mark for Oscar 2 with SphygmoCor Inside
04/05/15PRICE SENSITIVE
CDX Appendix 3B
31/03/15
CDX Appendix 3B
24/03/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
14.0¢ 		Change
-0.010(6.67%) 		Mkt cap ! $17.65M
Open High Low Value Volume
15.5¢ 17.5¢ 13.5¢ $186.0K 1.196M

Buyers (Bids)

No. Vol. Price($)
4 66974 13.5¢
 

Sellers (Offers)

Price($) Vol. No.
14.0¢ 14000 1
View Market Depth
Last trade - 13.57pm 15/11/2024 (20 minute delay) ?
Last
14.0¢ 		  Change
-0.010 ( 3.45 %)
Open High Low Volume
15.0¢ 17.0¢ 13.5¢ 497524
Last updated 14.31pm 15/11/2024 ?
CDX (ASX) Chart

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.